Form 4: WST Executive Converts RSUs, Sells Shares for Tax

A West Pharmaceutical Services executive converted restricted stock units into common stock and sold a portion to cover tax obligations.

Summary

• Rodolphe Jean Poussot, SVP, Strategy & Corporate Dev at West Pharmaceutical Services Inc. (WST), reported transactions under a pre-planned arrangement.
• On February 20, 2026, Poussot acquired 383.382 shares of common stock through the conversion of restricted stock units (RSUs).
• Simultaneously, Poussot disposed of 129.545 shares of common stock at a price of $241.12 per share, primarily to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Poussot beneficially owns 561.235 shares of common stock directly.
• The restricted stock units convert into common stock on a one-for-one basis.
• The RSUs involved were part of a grant of 1,143 units on February 20, 2024, which vest in three equal annual installments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While there's a sale of shares, it's for tax purposes related to RSU vesting, which is a routine and expected part of executive compensation, not an indication of a change in sentiment towards the company.

Positives

• The conversion of Restricted Stock Units (RSUs) into common stock indicates a vesting event, which is a standard part of executive compensation and retention.
• The executive continues to hold a significant number of shares (561.235) after the transactions, aligning their interests with shareholders.

Negatives

• The sale of 129.545 shares, even if for tax purposes, represents a reduction in the executive's direct ownership of common stock.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are common occurrences for executives in the pharmaceutical services industry, reflecting standard compensation practices designed to align executive incentives with long-term company performance.

Stakeholder Impact

• Shareholders: The executive's continued ownership of shares aligns their interests with long-term shareholder value, despite a small tax-related sale.

Next Steps

• Future vesting installments of the remaining restricted stock units granted on February 20, 2024.

Key Dates

Recommendation

The reported transactions are routine insider activity related to executive compensation and tax obligations, not indicative of a fundamental change in the company's prospects or the executive's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

West Pharmaceutical Services, WST, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Executive Compensation, Stock Sale, Tax Withholding